NCT02478099View on ClinicalTrials.gov

MPDL3280A-treatment-IST-UMCG

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

81

Participants

Timeline

Start Date

February 24, 2016

Primary Completion Date

September 19, 2023

Study Completion Date

July 31, 2024

Conditions

Locally Advanced or Metastatic Solid Tumors

Interventions

DRUG

MPDL3280A

Anti-PD-L1 antibody

Trial Locations (1)

9713 GZ

University Medical Center Groningen, Groningen

All Listed Sponsors

lead

University Medical Center Groningen

OTHER